{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T12:40:01Z","timestamp":1746362401799,"version":"3.40.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,26]],"date-time":"2014-08-26T00:00:00Z","timestamp":1409011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.bjid.2014.08.002","type":"journal-article","created":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T06:41:44Z","timestamp":1409553704000},"page":"15-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study"],"prefix":"10.1016","volume":"19","author":[{"given":"Paulo Roberto Abr\u00e3o","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariliza Henrique","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Eduardo","family":"Brand\u00e3o-Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosamar Eulira","family":"Rezende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rio","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T\u00e2nia","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose David","family":"Urbaez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinaldo Jose","family":"Gianini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C\u00e1ssia","family":"Mendes-Correa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2014.08.002_bib0005","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1413-8670(10)70050-7","article-title":"Barriers to the treatment of hepatitis C in HIV\/HCV-coinfected adults in Brazil","volume":"14","author":"Mendes-Corr\u00eaa","year":"2010","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.bjid.2014.08.002_bib0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/01.mcg.0000225592.16448.f3","article-title":"Hepatitis C in HIV-positive patients \u2013 treatment and liver disease outcomes","volume":"41","author":"Adeyemi","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.bjid.2014.08.002_bib0015","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkq086","article-title":"New direct-acting antivirals for hepatitis C: potential for interaction with antiretrovirals","volume":"65","author":"Seden","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2014.08.002_bib0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/17425255.2011.558839","article-title":"Approaches for understanding and predicting drug interactions in HIV-infected patients","volume":"7","author":"Jim\u00e9nez-N\u00e1cher","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.bjid.2014.08.002_bib0025","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1097\/QAD.0b013e32834bbb90","article-title":"Challenges and opportunities for hepatitis C drug development in HIV\/hepatitis C virus-coinfected patients","volume":"25","author":"Soriano","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.bjid.2014.08.002_bib0030","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2014.08.002_bib0035","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for the retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2014.08.002_bib0040","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2014.08.002_bib0045","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2014.08.002_bib0050","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(13)70149-X","article-title":"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial","volume":"13","author":"Sulkowski","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.bjid.2014.08.002_bib0055","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/0003-4819-159-2-201307160-00654","article-title":"Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial","volume":"159","author":"Sulkowski","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bjid.2014.08.002_bib0060","series-title":"Conference on Retroviruses and Opportunistic Infections (CROI 2014)","article-title":"Faldaprevir plus pegylated interferon alfa-2a\/ribavirin in HIV\/HCV coinfection: STARTVerso4","author":"Dieterich","year":"2014"},{"key":"10.1016\/j.bjid.2014.08.002_bib0065","series-title":"21st Conference on Retroviruses and Opportunistic Infections (CROI 2014)","article-title":"Simeprevir (TMC435) plus PegIFN\/ribavirin in HCV genotype-1\/HIV-1 coinfection (Study C212)","author":"Dieterich","year":"2014"},{"key":"10.1016\/j.bjid.2014.08.002_bib0070","series-title":"21st Conference on Retroviruses and Opportunistic Infections (CROI 2014)","article-title":"Sofosbuvir plus ribavirin for HCV genotype 1\u20133 infection in HIV coinfected patients (PHOTON-1)","author":"Naggie","year":"2014"},{"key":"10.1016\/j.bjid.2014.08.002_bib0075","series-title":"53rd ICAAC 2013","article-title":"Sofosbuvir and peginterferon alfa-2a\/ribavirin for treatment-na\u00efve genotype 1\u20134 HCV-infected patients who are coinfected with HIV","author":"Rodriguez-Torres","year":"2013"},{"unstructured":"http:\/\/www.aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-treatment-guidelines\/26\/hepatitis-c--hcv--hiv-coinfection [accessed 30.3.14].","key":"10.1016\/j.bjid.2014.08.002_bib0080"},{"key":"10.1016\/j.bjid.2014.08.002_bib0085","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection 2012 recommendations of the international antiviral society \u2013 USA panel","volume":"308","author":"Thompson","year":"2012","journal-title":"JAMA"},{"unstructured":"http:\/\/www.europeanaidsclinicalsociety.org\/index.php?option=com_content&view=article&id=59&Itemid=41 [accessed 28.7.12].","key":"10.1016\/j.bjid.2014.08.002_bib0090"},{"unstructured":"http:\/\/www.hcvguidelines.org\/full-report\/unique-patient-populations [accessed 30.3.14].","key":"10.1016\/j.bjid.2014.08.002_bib0095"},{"key":"10.1016\/j.bjid.2014.08.002_bib0100","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2014.08.002_bib0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for the treatment of HIV\/HCV-coinfected patients","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.bjid.2014.08.002_bib0110","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2014.08.002_bib0115","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.bjid.2014.08.002_bib0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00002030-200401020-00008","article-title":"Pegylated interferon a2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients","volume":"18","author":"Moreno","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.bjid.2014.08.002_bib0125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jhep.2005.05.019","article-title":"HCV clearance and treatment outcomes in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplant patients on peg-IFN-a-2b\/ribavirin","volume":"43","author":"Moreno","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2014.08.002_bib0130","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00002030-200305020-00011","article-title":"Pegylated IFNalpha 2b plus ribavirin as a treatment for chronic hepatitis C in HIV-infected patients","volume":"17","author":"P\u00e9rez-Olmeda","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.bjid.2014.08.002_bib0135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jinf.2005.09.007","article-title":"Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C","volume":"53","author":"Voigt","year":"2006","journal-title":"J Infect"},{"key":"10.1016\/j.bjid.2014.08.002_bib0140","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.bjid.2014.08.002_bib0145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2288-3-21","article-title":"Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio","volume":"3","author":"Barros","year":"2003","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.bjid.2014.08.002_bib0150","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bmj.316.7136.989","article-title":"When can odds ratios mislead?","volume":"316","author":"Davies","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.bjid.2014.08.002_bib0155","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the Cox Proportional Hazards Model","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bjid.2014.08.002_bib0160","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/jac\/dkp106","article-title":"Pegylated interferon alfa-2a plus ribavirin versus pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients","volume":"63","author":"Berenguer","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2014.08.002_bib0165","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s15010-008-7319-5","article-title":"Therapeutic aspects of and outcomes for HIV\/HCV-coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort","volume":"36","author":"Righi","year":"2008","journal-title":"Infection"},{"key":"10.1016\/j.bjid.2014.08.002_bib0170","first-page":"280","article-title":"The efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients coinfected with hepatitis C virus in clinical practice: a 32 case observational follow-up","volume":"26","author":"Righi","year":"2005","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.bjid.2014.08.002_bib0175","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/135965350801300818","article-title":"Differences in the virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV\/HIV-coinfected patients","volume":"13","author":"Tural","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bjid.2014.08.002_bib0180","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hep.22598","article-title":"A randomized trial comparing pegylated interferon alfa-2b to pegylated interferon alfa-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients","volume":"49","author":"Laguno","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bjid.2014.08.002_bib0185","doi-asserted-by":"crossref","first-page":"558","DOI":"10.5694\/j.1326-5377.2004.tb06447.x","article-title":"Generalizing the results of trials to clinical practice","volume":"181","author":"Seale","year":"2004","journal-title":"Med J Aust"},{"key":"10.1016\/j.bjid.2014.08.002_bib0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0197-2456(99)00054-9","article-title":"Impact of the Hawthorne effect in a longitudinal clinical study: the case of anesthesia","volume":"21","author":"De Amici","year":"2000","journal-title":"Control Clin Trials"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867014001664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867014001664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T12:17:02Z","timestamp":1746361022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867014001664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1413867014001664"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2014.08.002","relation":{},"ISSN":["1413-8670"],"issn-type":[{"type":"print","value":"1413-8670"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2014.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}